Achilles Therapeutics plc (NASDAQ:ACHL) Sees Large Growth in Short Interest

Achilles Therapeutics plc (NASDAQ:ACHL) was the target of a large increase in short interest during the month of March. As of March 31st, there was short interest totalling 74,800 shares, an increase of 8.6% from the March 15th total of 68,900 shares. Approximately 0.2% of the shares of the stock are short sold. Based on an average daily volume of 768,800 shares, the days-to-cover ratio is presently 0.1 days.

Achilles Therapeutics Trading Down 2.4 %

Achilles Therapeutics stock opened at $0.83 on Tuesday. Achilles Therapeutics has a 1 year low of $0.74 and a 1 year high of $1.76. The company has a market cap of $33.10 million, a PE ratio of -0.48 and a beta of 1.09. The company’s 50-day moving average is $1.14 and its two-hundred day moving average is $0.96.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Fcpm Iii Services B.V. acquired a new position in Achilles Therapeutics during the 4th quarter valued at about $2,127,000. Virtu Financial LLC acquired a new position in Achilles Therapeutics during the 4th quarter valued at about $35,000. Citadel Advisors LLC lifted its position in Achilles Therapeutics by 88.2% during the 4th quarter. Citadel Advisors LLC now owns 108,454 shares of the company’s stock valued at $96,000 after purchasing an additional 50,828 shares during the period. Vestal Point Capital LP acquired a new position in Achilles Therapeutics during the 4th quarter valued at about $96,000. Finally, Renaissance Technologies LLC increased its stake in shares of Achilles Therapeutics by 18.3% in the 2nd quarter. Renaissance Technologies LLC now owns 449,733 shares of the company’s stock valued at $425,000 after acquiring an additional 69,500 shares during the last quarter. 56.38% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

ACHL has been the topic of several research reports. Chardan Capital reduced their price target on shares of Achilles Therapeutics from $11.00 to $6.00 and set a “buy” rating on the stock in a research report on Friday, April 5th. Piper Sandler reiterated a “neutral” rating and set a $2.00 price target (down previously from $8.00) on shares of Achilles Therapeutics in a research report on Friday, April 5th.

About Achilles Therapeutics

Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma.